This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Prurigo Nodularis Treatment Market

Market Insights on Prurigo Nodularis Treatment covering sales outlook, demand forecast & up-to-date key trends

Prurigo Nodularis Treatment Market by Drug Class (CorticosteroidsInjectable, Capsaicin Cream, Antihistamines, Anticonvulsants, Antidepressants, Neurokinin 1 Receptor (NK1R), Opiate Receptor Antagonists), Distribution Channel & Region - Forecast to 2020-2030

Prurigo Nodularis Treatment Market - About the Report

[210 Pages Report] Prurigo nodularis is categorized as a skin condition that leads to the formation of hard, itchy nodules or lumps on the surface of the skin. This rare and chronic inflammatory disorder can appear on arms, lower limbs, shoulders, buttocks, and other areas of the body. Prurigo Nodularis is more prevalent among adults between 20 to 60 years of age group, especially the ones suffering from HIV and atopic dermatitis. Whereas, there has been a significant increase in treatment adoption rate with increasing awareness owing to Prurigo Nodularis Treatment Market growth.

In its new study, ESOMAR-certified market research and consulting firm Future Market Insights offers insights about key factors driving demand for prurigo nodularis treatment. The report tracks global sales of prurigo nodularis treatment drugs in 20+ high-growth markets, where major traction is being witnessed in North America, followed by Europe. 

Customize this Report

Let us know your requirement to get
100% FREE customization

How Does Historic and Future Outlook For Prurigo Nodularis Treatment Market Match Up?

Initiatives such as activities and programmes undertaken for increasing the awareness about rare diseases and therapeutic options available are expected to fuel the demand for prurigo nodularis treatment. Organizations such as the National Organization for Rare Disorders (NORD) is dedicated to the offering required treatment and spreading awareness among the patients suffering from rare diseases.

Increasing advancement of technology and strategic collaboration undertaken by leading market players have paved way for innovations in prurigo nodularis treatment. For instance, in 2019 Aurobindo Pharma Ltd. has announced its decision to purchase Novartis AG unit Sandoz Inc.’s dermatology and generic pills business for US$ 1 billion leading to market expansion for prurigo nodularis treatment.

According to Future Market Insight’s analysis, the prurigo nodularis treatment market expanded at 3.8 % CAGR from 2015 to 2019.

Regions with poor economic conditions rely on the import of drugs and raw material for the treatment of prurigo nodularis. COVID 19 has led to large scale closures of manufacturing units and disruption in supply chain activities, impacting prurigo nodularis treatment market growth for the short duration of time. On the other hand, there was a significant decline in hospital-patient visits resulting in lower diagnosis in prurigo nodualris. Future Market Insights expects the global prurigo nodularis treatment market to progress at 3% CAGR through 2030.

How are the Favourable Regulations Impacting Prurigo Nodularis Treatment Demand?

Regulatory bodies are continuously trying to create favourable scenarios for the development and commercialization of orphan drugs catering to patients suffering from rare diseases. These regulations help in speeding up the development and approval process of drugs under investigation. 

For instance, the U.S. Food and Drug Administration (FDA) has dedicated Orphan Products Development (OOPD) office to advance the assessment and development of products that include drugs, biologics, medical food and devices. Hence, these favourable regulations for the development of orphan drugs are expected to boost demand for prurigo nodularis treatment market.

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

How is Improvement in Outpatient Services Affecting Prurigo Nodularis Treatment Market?

There has been significant funds and industry investment allocation towards developing and improving healthcare infrastructure in developing regions. As a result, there is a rising number of ambulatory care centres and dermatology clinics across the globe. This has been creating growth opportunities for the prurigo nodularis treatment market by increasing scope for diagnosis and treatment of the condition.

Clinical innovation, financial incentives and patient preferences will improve outpatient services for prurigo nodularis treatment. On the other hand, prurigo nodularis has the highest prevalence rate among patients suffering from atopic dermatitis. According to the National Eczema Association, approximately 31.6 million people across the globe suffer from atopic dermatitis. Therefore, with ease of treatment on an outpatient basis, there will be significant growth opportunities for the prurigo nodularis treatment market.

Share of drug class differs in key markets, the following chart presents the elucidated view of the drug class share concerning key regions. In the top 7 regions which include North America, Latin America, Europe, South Asia, East Asia, Oceania and the Middle East & Africa, the share of Europe is significantly high, in comparison to other regions and among drug class capsaicin cream accounts for the leading share of the market. Corticosteroids is also a mass category drug class, as it holds the second position in terms of demand across all key regions.

Prurigo Nodularis Treatment Market - Country-wise Insights

How big is the Opportunity in France for Prurigo Nodularis Treatment?

Future Market Insights has projected France to remain the most lucrative market throughout the forecast period. One of the key factors supporting market expansion is the increasing prevalence of prurigo nodularis.

The increasing rate of approval and commercialization of drugs for prurigo nodularis treatment in Europe is expected to boost the market. Also, the majority of the key players have their headquarters based in Europe, which is supporting growth exhibited in the region.

France remains one of the leading countries with high-level advanced technology for diagnosis and treatment of prurigo nodularis. The market in France is expected to progress at a significant CAGR of over 3% during the forecast period.

What are the Restrains that GCC Countries Face in Prurigo Nodularis Treatment?

There is significantly less awareness about rare diseases including prurigo nodularis and its therapeutic options available in GCC countries challenging prurigo nodularis treatment market growth. On the other hand, poor economic conditions and healthcare infrastructure hinders the adoption of prurigo nodularis treatment across GCC countries. Dependency on developed countries for drug, raw materials, skilled labour and advanced technology therapeutics restraints the GCC countries prurigo nodularis treatment market growth.

Whereas, there is the increasing demand for prurigo nodularis treatment across GCC countries with increasing prevalence rate and increasing awareness campaigns/activities. The prurigo nodularis treatment market in GCC countries is expected to witness healthy growth at a CAGR of just around 5%.

What is the Contribution of U.S. in the Market of Prurigo Nodularis Treatment?

The U.S. is one of the leading countries exhibiting demand for prurigo nodularis treatment demand. The presence of highly developed healthcare infrastructure with the availability of skilled labour is driving prospects within the country. The U.S. is expected to register growth at around 2% CAGR through the forecast period. The country showcases increasing investment towards research and development activities on biopharmaceuticals aimed at developing cure of rare diseases. 

The U.S. also has been exhibiting a high rate of diagnosis and treatment adoption for prurigo nodularis as compared to other countries. The country exhibits presence of some of the leading biopharmaceutical companies and has a high rate of approval and commercialization for prurigo nodularis treatment drugs. On the other hand, it has lesser prevalence of prurigo nodularis as compared to countries in Europe, Latin America and Middle East & Africa regions.

How Attractive Is The Indian Market For Prurigo Nodularis Treatment?

There has been a significant rise in the number of domestic pharmaceutical manufacturing players in past few years in India. The Indian pharmaceutical industry is said to hold a high rank globally in terms of volume of biopharma products manufactured. The India market is set to exhibit nearly 4% CAGR over the forecast period. Some of the leading player operating in the are attracted towards investing or setting up a manufacturing plant in India due to less labour cost and high manufacturing capacities.

From past decade India has been exhibiting increasing investment towards healthcare infrastructure. Besides this, the moderate prevalence rate of prurigo nodularis and increasing treatment adoption rate are expected to fuel demand in the country.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Prurigo Nodularis Treatment Market - Category-wise Insights

Why is Capsaicin Cream highly Sought-after in Prurigo Nodularis Treatment? 

Capsaicin cream accounts for over 40% of the global share among drug class through the forecast period. This is due to the increasing demand for topical drugs that are easy to apply and more effective hence capsaicin cream holds the majority of revenue share for prurigo nodularis treatment market. 

Prurigo Nodularis Treatment Market Download Report Brochure

Why is Demand for Retail Pharmacies More among Prurigo Nodularis Treatment Distribution Channel?

Revenue from retails pharmacies is expected to increase by 1.5X by 2030-end as compared to that in 2019. Easing regulatory guidelines for orphan drugs used in the treatment of prurigo nodularis is expected to boost demand for prurigo nodularis treatment market during the forecast period.

Retail pharmacies with the well-developed supply chain activities for trading across borders is the leading distribution channel for prurigo nodularis treatment market. On the other hand, with the increasing adaption of e-commerce activities, online pharmacies will observe high growth rate in the coming decade.

Prurigo Nodularis Treatment Market - Competitive Landscape

Leading market players are focusing on expanding their product portfolio with strategic collaborations and product innovations. Key players are also adopting merger and acquisition strategies for increasing their presence and attracting investments across the globe in prurigo nodularis treatment market. For instance, in April 2020, VYNE Therapeutics from New Jersey released its results from two Phase 3 trials for a key product an oral drug “serlopitant” used in the treatment of prurigo nodularis. 

Some of the leading companies operating in the market are: 

  • Bayer AG
  • Pfizer Inc.
  • GlaxoSmithKline Plc.
  • Teva Pharmaceutical Industries Ltd.
  • Johnson & Johnson Services, Inc.
  • Merck & Co. Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Novartis AG
  • Celgene Corporation
  • Galderma SA (Nestle Skin Health Company)
  • VYNE Therapeutics Inc.
  • Trevi Therapeutics Inc.

*The list is not exhaustive, and only for representational purposes. Full competitive intelligence with SWOT analysis available in the report. 

Prurigo Nodularis Treatment Market - Scope of Report

Attribute

Details

Forecast Period

2020-2030

Historical Data Available for

2015-2019

Prurigo Nodularis Treatment Market Analysis

USD Million for Value

Key Regions Covered

North America, Latin America, Europe, South Asia, East Asia, Oceania, and the Middle East & Africa

Key Countries Covered

U.S., Canada, Brazil, Mexico, Argentina, Germany, Italy, France, U.K., Spain, BENELUX, Russia, India, Thailand, Indonesia, Malaysia, China, Japan, South Korea, Australia, New Zealand, GCC Countries and South Africa

Key Segments Covered

Drug Class, Distribution Channel, and Region

Key Companies Profiled

  • Bayer AG
  • Pfizer, Inc.
  • GlaxoSmithKline Plc.
  • Teva Pharmaceutical Industries Ltd.
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Novartis AG
  • Celgene Corporation
  • Galderma SA (Nestle Skin Health Company)
  • VYNE Therapeutics Inc.
  • Trevi Therapeutics, Inc,

Prurigo Nodularis Treatment Market Report Coverage

Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives

Customization & Pricing

Available upon Request

Prurigo nodularis treatment Market by Category

Drug Class:

  • CorticosteroidsInjectable
    • Topical
    • Oral
    • Emollients
  • Capsaicin Cream
  • Antihistamines
  • Anticonvulsants
  • Antidepressants
  • Neurokinin 1 Receptor (NK1R)
  • Opiate Receptor Antagonists
  • Others

Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online sales

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East and Africa (MEA)

Frequently Asked Questions

The Europe prurigo nodularis treatment market has the highest market share. Moreover, the high prevalence of prurigo nodularis and increasing diagnosis and treatment adoption rate is creating growth for the market in Europe. France currently leads the global market for prurigo nodularis treatment, with revenue expected to reach US$ 86 Mn by 2030.

Capsaicin cream is expected to be most lucrative segment among the drug class with the increasing demand for easy to apply and topical therapies as compared to other drugs, and the segment is expected continue to expand at a CAGR of more than 3% over the next ten years.

Some of the leading companies offering prurigo nodularis treatment drugs are Bayer AG, Pfizer Inc., GlaxoSmithKline Plc., Teva Pharmaceutical Industries Ltd., Johnson & Johnson Services, Inc., Merck & Co. Inc., Sanofi SA, Takeda Pharmaceutical Company Limited, Novartis AG, Celgene Corporation, Galderma SA, VYNE Therapeutics Inc., and Trevi Therapeutics, Inc.

Retail pharmacies are expected to dominate the prurigo nodularis treatment market over the forecast period. On the other hand, online pharmacies will have significant growth in the coming decade with increasing adoption of e-commerce activities across the globe.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand Side Trends

    1.3. Supply Side Trends

    1.4. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

    2.3. Inclusion & Exclusion

3. Key Market Trends

    3.1. Drug Innovation & Development Trends

4. Key Success Factors

    4.1. Drug Adoption & Awareness Analysis

    4.2. Drug Pipeline Assessment

    4.3. Diseases Epidemiology, By Region

    4.4. Value Chain

5. Global Prurigo Nodularis Treatment Market Demand (in Value or Size in US$ Mn) Analysis 2015-2019 and Forecast, 2020-2030

    5.1. Historical Market Value (US$ Mn) Analysis, 2015-2019

    5.2. Current and Future Market Value (US$ Mn) Projections, 2020-2030

        5.2.1. Y-o-Y Growth Trend Analysis

        5.2.2. Absolute $ Opportunity Analysis

6. Market Background

    6.1. Macro-Economic Factors

        6.1.1. Global GDP Growth Outlook

        6.1.2. Global Healthcare Expenditure Outlook

        6.1.3. Growth of Healthcare Sector in Emerging Nations

    6.2. Forecast Factors - Relevance & Impact

        6.2.1. Prevalence of Prurigo Nodularis

        6.2.2. Advancements in Prurigo Nodularis Treatment

        6.2.3. Prevalence of HIV

        6.2.4. Acceptance of Treatment Products by Prescribers

        6.2.5. Healthcare Expenditure

        6.2.6. Product Penetration Rate across End Users

        6.2.7. Product Launches

        6.2.8. Drug Cost

        6.2.9. Penetration of Product in Different Distribution Channel

    6.3. Market Dynamics

        6.3.1. Drivers

        6.3.2. Restraints

        6.3.3. Opportunity Analysis

7. COVID19 Crisis Analysis

    7.1. Current COVID19 Statistics and Probable Future Impact

    7.2. Current GDP Projection and Probable Impact

    7.3. Current Economic Projection as compared to 2008 financial analysis

    7.4. COVID19 and Impact Analysis

        7.4.1. Revenue by Drug Class

        7.4.2. Revenue by Distribution Channel

        7.4.3. Revenue by Region

    7.5. 2020 Market Scenario

    7.6. Quarter by Quarter Forecast

    7.7. Projected recovery Quarter

    7.8. Recovery Scenario – Short term, Midterm and Long Term Impact

8. Global Prurigo Nodularis Treatment Market Analysis 2015-2019 and Forecast 2020-2030, by Drug Class 

    8.1. Introduction / Key Findings

    8.2. Historical Market Size (US$ Mn) Analysis by Drug Class, 2015 - 2019

    8.3. Current and Future Market Size (US$ Mn) and Forecast by Drug Class, 2020 - 2030

        8.3.1. Corticosteroids

            8.3.1.1. Injectable

            8.3.1.2. Topical

            8.3.1.3. Oral

        8.3.2. Emollients

        8.3.3. Capsaicin Cream

        8.3.4. Antihistamines

        8.3.5. Anticonvulsants

        8.3.6. Antidepressants

        8.3.7. Neurokinin 1 Receptor (NK1R)

        8.3.8. Opiate Receptor Antagonists

        8.3.9. Others

    8.4. Market Attractiveness Analysis by Drug Class 

9. Global Prurigo Nodularis Treatment Market Analysis 2015-2019 and Forecast 2020-2030, by Distribution Channel 

    9.1. Introduction / Key Findings

    9.2. Historical Market Size (US$ Mn) Analysis by Distribution Channel, 2015 - 2019

    9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Distribution Channel, 2020 - 2030

        9.3.1. Hospital Pharmacies

        9.3.2. Retail Pharmacies

        9.3.3. Online Pharmacies 

    9.4. Market Attractiveness Analysis by Distribution Channel

10. Global Prurigo Nodularis Treatment Market Analysis 2015-2019 and Forecast 2020-2030, by Region

    10.1. Introduction

    10.2. Historical Market Size (US$ Mn) Analysis by Region, 2015 - 2019

    10.3. Current Market Size (US$ Mn) Analysis and Forecast by Region, 2020 - 2030

        10.3.1. North America

        10.3.2. Latin America

        10.3.3. Europe

        10.3.4. Middle East and Africa (MEA)

        10.3.5. East Asia

        10.3.6. South Asia

        10.3.7. Oceania

    10.4. Market Attractiveness Analysis by Region

11. North America Prurigo Nodularis Treatment Market Analysis 2015-2019 and Forecast 2020-2030

    11.1. Introduction

    11.2. Historical Market Size (US$ Mn) Trend Analysis by Market Taxonomy, 2015 - 2019

    11.3. Market Size (US$ Mn) Forecast by Market Taxonomy, 2020 - 2030

        11.3.1. By Country

            11.3.1.1. U.S.

            11.3.1.2. Canada

        11.3.2. By Drug Class

        11.3.3. By Distribution Channel

    11.4. Market Attractiveness Analysis

        11.4.1. By Country

        11.4.2. By Drug Class

        11.4.3. By Distribution Channel

    11.5. Drivers and Restraints - Impact Analysis

12. Latin America Prurigo Nodularis Treatment Market 2015-2019 and Forecast 2020-2030

    12.1. Introduction

    12.2. Historical Market Size (US$ Mn) Trend Analysis by Market Taxonomy, 2015 - 2019

    12.3. Market Size (US$ Mn) Forecast by Market Taxonomy, 2020 - 2030

        12.3.1. By Country

            12.3.1.1. Brazil

            12.3.1.2. Mexico

            12.3.1.3. Argentina

            12.3.1.4. Rest of Latin America

        12.3.2. By Drug Class

        12.3.3. By Distribution Channel

    12.4. Market Attractiveness Analysis

        12.4.1. By Country

        12.4.2. By Drug Class

        12.4.3. By Distribution Channel

    12.5. Drivers and Restraints - Impact Analysis

13. Europe Prurigo Nodularis Treatment Market 2015-2019 and Forecast 2020-2030

    13.1. Introduction

    13.2. Historical Market Size (US$ Mn) Trend Analysis by Market Taxonomy, 2015 - 2019

    13.3. Market Size (US$ Mn) Forecast by Market Taxonomy, 2020 - 2030

        13.3.1. By Country

            13.3.1.1. Germany

            13.3.1.2. Italy

            13.3.1.3. France

            13.3.1.4. U.K.

            13.3.1.5. Spain

            13.3.1.6. BENELUX

            13.3.1.7. Russia

            13.3.1.8. Rest of Europe

        13.3.2. By Drug Class

        13.3.3. By Distribution Channel

    13.4. Market Attractiveness Analysis

        13.4.1. By Country

        13.4.2. By Drug Class

        13.4.3. By Distribution Channel

    13.5. Drivers and Restraints - Impact Analysis

14. South Asia Prurigo Nodularis Treatment Market 2015-2019 and Forecast 2020-2030

    14.1. Introduction

    14.2. Historical Market Size (US$ Mn) Trend Analysis by Market Taxonomy, 2015 - 2019

    14.3. Market Size (US$ Mn) Forecast by Market Taxonomy, 2020 - 2030

        14.3.1. By Country

            14.3.1.1. India

            14.3.1.2. Thailand

            14.3.1.3. Indonesia

            14.3.1.4. Malaysia

            14.3.1.5. Rest of South Asia

        14.3.2. By Drug Class

        14.3.3. By Distribution Channel

    14.4. Market Attractiveness Analysis

        14.4.1. By Country

        14.4.2. By Drug Class

        14.4.3. By Distribution Channel

    14.5. Drivers and Restraints - Impact Analysis

15. East Asia Prurigo Nodularis Treatment Market 2015-2019 and Forecast 2020-2030

    15.1. Introduction

    15.2. Historical Market Size (US$ Mn) Trend Analysis by Market Taxonomy, 2015 - 2019

    15.3. Market Size (US$ Mn) Forecast by Market Taxonomy, 2020 - 2030

        15.3.1. By Country

            15.3.1.1. China

            15.3.1.2. Japan

            15.3.1.3. South Korea

        15.3.2. By Drug Class

        15.3.3. By Distribution Channel

    15.4. Market Attractiveness Analysis

        15.4.1. By Country

        15.4.2. By Drug Class

        15.4.3. By Distribution Channel

    15.5. Drivers and Restraints - Impact Analysis

16. Oceania Prurigo Nodularis Treatment Market 2015-2019 and Forecast 2020-2030

    16.1. Introduction

    16.2. Historical Market Size (US$ Mn) Trend Analysis by Market Taxonomy, 2015 - 2019

    16.3. Market Size (US$ Mn) Forecast by Market Taxonomy, 2020 - 2030

        16.3.1. By Country

            16.3.1.1. Australia

            16.3.1.2. New Zealand

        16.3.2. By Drug Class

        16.3.3. By Distribution Channel

    16.4. Market Attractiveness Analysis

        16.4.1. By Country

        16.4.2. By Drug Class

        16.4.3. By Distribution Channel

    16.5. Drivers and Restraints - Impact Analysis

17. Middle East and Africa Prurigo Nodularis Treatment Market 2015-2019 and Forecast 2020-2030

    17.1. Introduction

    17.2. Historical Market Size (US$ Mn) Trend Analysis by Market Taxonomy, 2015 - 2019

    17.3. Market Size (US$ Mn) Forecast by Market Taxonomy, 2020 - 2030

        17.3.1. By Country

            17.3.1.1. GCC Countries

            17.3.1.2. South Africa

            17.3.1.3. Rest of Middle East and Africa

        17.3.2. By Drug Class

        17.3.3. By Distribution Channel

    17.4. Market Attractiveness Analysis

        17.4.1. By Country

        17.4.2. By Drug Class

        17.4.3. By Distribution Channel

    17.5. Drivers and Restraints - Impact Analysis

18. Emerging & Key Countries Prurigo Nodularis Treatment Market Analysis 

    18.1. Introduction

        18.1.1. Market Value Proportion Analysis, By Key Countries

        18.1.2. Global Vs. Country Growth Comparison

    18.2. U.S. Prurigo Nodularis Treatment Market Analysis

        18.2.1. By Drug Class

        18.2.2. By Distribution Channel

    18.3. Canada Prurigo Nodularis Treatment Market Analysis

        18.3.1. By Drug Class

        18.3.2. By Distribution Channel

    18.4. Mexico Prurigo Nodularis Treatment Market Analysis

        18.4.1. By Drug Class

        18.4.2. By Distribution Channel

    18.5. Brazil Prurigo Nodularis Treatment Market Analysis

        18.5.1. By Drug Class

        18.5.2. By Distribution Channel

    18.6. Germany Prurigo Nodularis Treatment Market Analysis

        18.6.1. By Drug Class

        18.6.2. By Distribution Channel

    18.7. Italy Prurigo Nodularis Treatment Market Analysis

        18.7.1. By Drug Class

        18.7.2. By Distribution Channel

    18.8. France Prurigo Nodularis Treatment Market Analysis

        18.8.1. By Drug Class

        18.8.2. By Distribution Channel

    18.9. U.K. Prurigo Nodularis Treatment Market Analysis

        18.9.1. By Drug Class

        18.9.2. By Distribution Channel

    18.10. Spain Prurigo Nodularis Treatment Market Analysis

        18.10.1. By Drug Class

        18.10.2. By Distribution Channel

    18.11. Russia Prurigo Nodularis Treatment Market Analysis

        18.11.1. By Drug Class

        18.11.2. By Distribution Channel

    18.12. China Prurigo Nodularis Treatment Market Analysis

        18.12.1. By Drug Class

        18.12.2. By Distribution Channel

    18.13. Japan Prurigo Nodularis Treatment Market Analysis

        18.13.1. By Drug Class

        18.13.2. By Distribution Channel

    18.14. S. Korea Prurigo Nodularis Treatment Market Analysis

        18.14.1. By Drug Class

        18.14.2. By Distribution Channel

    18.15. India Prurigo Nodularis Treatment Market Analysis

        18.15.1. By Drug Class

        18.15.2. By Distribution Channel

    18.16. Thailand Prurigo Nodularis Treatment Market Analysis

        18.16.1. By Drug Class

        18.16.2. By Distribution Channel

    18.17. Malaysia Prurigo Nodularis Treatment Market Analysis

        18.17.1. By Drug Class

        18.17.2. By Distribution Channel

    18.18. Indonesia Prurigo Nodularis Treatment Market Analysis

        18.18.1. By Drug Class

        18.18.2. By Distribution Channel

    18.19. Australia and New Zealand Prurigo Nodularis Treatment Market Analysis

        18.19.1. By Drug Class

        18.19.2. By Distribution Channel

    18.20. GCC Countries Prurigo Nodularis Treatment Market Analysis

        18.20.1. By Drug Class

        18.20.2. By Distribution Channel

    18.21. South Africa Prurigo Nodularis Treatment Market Analysis

        18.21.1. By Drug Class

        18.21.2. By Distribution Channel

19. Market Structure Analysis

    19.1. Market Analysis by Tier of Companies 

    19.2. Market Concentration

20. Competition Analysis

    20.1. Competition Dashboard

    20.2. Competition Benchmarking

    20.3. Competition Deep Dive 

    20.4. Key Players Based On Estimated Tracked Revenue 

        20.4.1. Bayer AG

            20.4.1.1. Drug Class Portfolio

            20.4.1.2. Profitability by Market Segments (Drug Class/Region)

            20.4.1.3. Sales Footprint

            20.4.1.4. Analyst commentary

            20.4.1.5. Strategy Overview

                20.4.1.5.1. Marketing Strategy

                20.4.1.5.2. Drug Class Strategy

                20.4.1.5.3. Distribution Channel Strategy

        20.4.2. Pfizer Inc.

            20.4.2.1. Drug Class Portfolio

            20.4.2.2. Profitability by Market Segments (Drug Class/Region)

            20.4.2.3. Sales Footprint

            20.4.2.4. Analyst commentary

            20.4.2.5. Strategy Overview

                20.4.2.5.1. Marketing Strategy

                20.4.2.5.2. Drug Class Strategy

                20.4.2.5.3. Distribution Channel Strategy

        20.4.3. GlaxoSmithKline plc

            20.4.3.1. Drug Class Portfolio

            20.4.3.2. Profitability by Market Segments (Drug Class/Region)

            20.4.3.3. Sales Footprint

            20.4.3.4. Analyst commentary

            20.4.3.5. Strategy Overview

                20.4.3.5.1. Marketing Strategy

                20.4.3.5.2. Drug Class Strategy

                20.4.3.5.3. Distribution Channel Strategy

        20.4.4. Teva Pharmaceutical Industries Ltd

            20.4.4.1. Drug Class Portfolio

            20.4.4.2. Profitability by Market Segments (Drug Class/Region)

            20.4.4.3. Sales Footprint

            20.4.4.4. Analyst commentary

            20.4.4.5. Strategy Overview

                20.4.4.5.1. Marketing Strategy

                20.4.4.5.2. Drug Class Strategy

                20.4.4.5.3. Distribution Channel Strategy

        20.4.5. Johnson & Johnson Services, Inc.

            20.4.5.1. Drug Class Portfolio

            20.4.5.2. Profitability by Market Segments (Drug Class/Region)

            20.4.5.3. Sales Footprint

            20.4.5.4. Analyst commentary

            20.4.5.5. Strategy Overview

                20.4.5.5.1. Marketing Strategy

                20.4.5.5.2. Drug Class Strategy

                20.4.5.5.3. Distribution Channel Strategy

        20.4.6. Merck & Co. Inc.

            20.4.6.1. Drug Class Portfolio

            20.4.6.2. Profitability by Market Segments (Drug Class/Region)

            20.4.6.3. Sales Footprint

            20.4.6.4. Analyst commentary

            20.4.6.5. Strategy Overview

                20.4.6.5.1. Marketing Strategy

                20.4.6.5.2. Drug Class Strategy

                20.4.6.5.3. Distribution Channel Strategy

        20.4.7. Sanofi SA

            20.4.7.1. Drug Class Portfolio

            20.4.7.2. Profitability by Market Segments (Drug Class/Region)

            20.4.7.3. Sales Footprint

            20.4.7.4. Analyst commentary

            20.4.7.5. Strategy Overview

                20.4.7.5.1. Marketing Strategy

                20.4.7.5.2. Drug Class Strategy

                20.4.7.5.3. Distribution Channel Strategy

        20.4.8. Takeda Pharmaceutical Company Limited

            20.4.8.1. Drug Class Portfolio

            20.4.8.2. Profitability by Market Segments (Drug Class/Region)

            20.4.8.3. Sales Footprint

            20.4.8.4. Analyst commentary

            20.4.8.5. Strategy Overview

                20.4.8.5.1. Marketing Strategy

                20.4.8.5.2. Drug Class Strategy

                20.4.8.5.3. Distribution Channel Strategy

        20.4.9. Novartis AG

            20.4.9.1. Drug Class Portfolio

            20.4.9.2. Profitability by Market Segments (Drug Class/Region)

            20.4.9.3. Sales Footprint

            20.4.9.4. Analyst commentary

            20.4.9.5. Strategy Overview

                20.4.9.5.1. Marketing Strategy

                20.4.9.5.2. Drug Class Strategy

                20.4.9.5.3. Distribution Channel Strategy

        20.4.10. Celgene Corporation

            20.4.10.1. Drug Class Portfolio

            20.4.10.2. Profitability by Market Segments (Drug Class/Region)

            20.4.10.3. Sales Footprint

            20.4.10.4. Analyst commentary

            20.4.10.5. Strategy Overview

                20.4.10.5.1. Marketing Strategy

                20.4.10.5.2. Drug Class Strategy

                20.4.10.5.3. Distribution Channel Strategy

        20.4.11. Galderma SA (Nestle Skin Health Company)

            20.4.11.1. Drug Class Portfolio

            20.4.11.2. Profitability by Market Segments (Drug Class/Region)

            20.4.11.3. Sales Footprint

            20.4.11.4. Analyst commentary

            20.4.11.5. Strategy Overview

                20.4.11.5.1. Marketing Strategy

                20.4.11.5.2. Drug Class Strategy

                20.4.11.5.3. Distribution Channel Strategy

        20.4.12. VYNE Therapeutics Inc.

            20.4.12.1. Drug Class Portfolio

            20.4.12.2. Profitability by Market Segments (Drug Class/Region)

            20.4.12.3. Sales Footprint

            20.4.12.4. Analyst commentary

            20.4.12.5. Strategy Overview

                20.4.12.5.1. Marketing Strategy

                20.4.12.5.2. Drug Class Strategy

                20.4.12.5.3. Distribution Channel Strategy

        20.4.13. Trevi Therapeutics, Inc.

            20.4.13.1. Drug Class Portfolio

            20.4.13.2. Profitability by Market Segments (Drug Class/Region)

            20.4.13.3. Sales Footprint

            20.4.13.4. Analyst commentary

            20.4.13.5. Strategy Overview

                20.4.13.5.1. Marketing Strategy

                20.4.13.5.2. Drug Class Strategy

                20.4.13.5.3. Distribution Channel Strategy

21. Assumptions and Acronyms Used

22. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 01: Global Prurigo Nodularis Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Drug Class

Table 02: Global Prurigo Nodularis Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Distribution Channel

Table 03: Global Prurigo Nodularis Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Region

Table 04: North America Prurigo Nodularis Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Country

Table 05: North America Prurigo Nodularis Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Drug Class

Table 06: North America Prurigo Nodularis Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Distribution Channel

Table 07: Latin America Prurigo Nodularis Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Country

Table 08: Latin America Prurigo Nodularis Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Drug Class

Table 09: Latin America Prurigo Nodularis Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Distribution Channel

Table 10: Europe Prurigo Nodularis Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Country

Table 11: Europe Prurigo Nodularis Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Drug Class

Table 12: Europe Prurigo Nodularis Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Distribution Channel

Table 13: South Asia Prurigo Nodularis Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Country

Table 14: South Asia Prurigo Nodularis Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Drug Class

Table 15: South Asia Prurigo Nodularis Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Distribution Channel

Table 16: East Asia Prurigo Nodularis Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Country

Table 17: East Asia Prurigo Nodularis Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Drug Class

Table 18: East Asia Prurigo Nodularis Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Distribution Channel

Table 19: Oceania Prurigo Nodularis Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Country

Table 20: Oceania Prurigo Nodularis Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Drug Class

Table 21: Oceania Prurigo Nodularis Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Distribution Channel

Table 22: Middle East and Africa Prurigo Nodularis Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Country

Table 23: Middle East and Africa Prurigo Nodularis Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Drug Class

Table 24: Middle East and Africa Prurigo Nodularis Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Distribution Channel

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst
List of Charts

Figure 01: Global Prurigo Nodularis Treatment Market Value Analysis (US$ Mn), 2015-2019

Figure 02: Global Prurigo Nodularis Treatment Market Value Forecast (US$ Mn), 2020-2030

Figure 03: Global Prurigo Nodularis Treatment Market Absolute $ Opportunity, 2020 - 2030

Figure 04: Global Prurigo Nodularis Treatment Market Share Analysis (%), By Drug Class, 2020-2030

Figure 05: Global Prurigo Nodularis Treatment Market Y-o-Y Analysis (%), By Drug Class, 2020-2030

Figure 06: Global Prurigo Nodularis Treatment Market Attractiveness Analysis By Drug Class, 2020-2030

Figure 07: Global Prurigo Nodularis Treatment Market Share Analysis (%), By Distribution Channel, 2020-2030

Figure 08: Global Prurigo Nodularis Treatment Market Y-o-Y Analysis (%), By Distribution Channel, 2020-2030

Figure 09: Global Prurigo Nodularis Treatment Market Attractiveness Analysis By Distribution Channel, 2020-2030

Figure 10: Global Prurigo Nodularis Treatment Market Share Analysis (%), By Region, 2020-2030

Figure 11: Global Prurigo Nodularis Treatment Market Y-o-Y Analysis (%), By Region, 2020-2030

Figure 12: Global Prurigo Nodularis Treatment Market Attractiveness Analysis By Region, 2020-2030

Figure 13: North America Prurigo Nodularis Treatment Market Value Share, By Drug Class, 2020 (E)

Figure 14: North America Prurigo Nodularis Treatment Market Value Share, By Distribution Channel, 2020 (E)

Figure 15: North America Prurigo Nodularis Treatment Market Value Share, By Country, 2020 (E)

Figure 16: North America Prurigo Nodularis Treatment Market Value Analysis (US$ Mn), 2015-2019

Figure 17: North America Prurigo Nodularis Treatment Market Value Forecast (US$ Mn), 2020-2030

Figure 18: North America Prurigo Nodularis Treatment Market Attractiveness Analysis By Drug Class, 2020-2030

Figure 19: North America Prurigo Nodularis Treatment Market Attractiveness Analysis by Distribution Channel, 2020-2030

Figure 20: North America Prurigo Nodularis Treatment Market Attractiveness Analysis by Country, 2020-2030

Figure 21: Latin America Prurigo Nodularis Treatment Market Value Share, By Drug Class, 2020 (E)

Figure 22: Latin America Prurigo Nodularis Treatment Market Value Share, By Distribution Channel, 2020 (E)

Figure 23: Latin America Prurigo Nodularis Treatment Market Value Share, By Country, 2020 (E)

Figure 24: Latin America Prurigo Nodularis Treatment Market Value Analysis (US$ Mn), 2015-2019

Figure 25: Latin America Prurigo Nodularis Treatment Market Value Forecast (US$ Mn), 2020-2030

Figure 26: Latin America Prurigo Nodularis Treatment Market Attractiveness Analysis By Drug Class, 2020-2030

Figure 27: Latin America Prurigo Nodularis Treatment Market Attractiveness Analysis by Distribution Channel, 2020-2030

Figure 28: Latin America Prurigo Nodularis Treatment Market Attractiveness Analysis by Country, 2020-2030

Figure 29: Europe Prurigo Nodularis Treatment Market Value Share, By Drug Class, 2020 (E)

Figure 30: Europe Prurigo Nodularis Treatment Market Value Share, By Distribution Channel, 2020 (E)

Figure 31: Europe Prurigo Nodularis Treatment Market Value Share, By Country, 2020 (E)

Figure 32: Europe Prurigo Nodularis Treatment Market Value Analysis (US$ Mn), 2015-2019

Figure 33: Europe Prurigo Nodularis Treatment Market Value Forecast (US$ Mn), 2020-2030

Figure 34: Europe Prurigo Nodularis Treatment Market Attractiveness Analysis By Drug Class, 2020-2030

Figure 35: Europe Prurigo Nodularis Treatment Market Attractiveness Analysis by Distribution Channel, 2020-2030

Figure 36: Europe Prurigo Nodularis Treatment Market Attractiveness Analysis by Country, 2020-2030

Figure 37: South Asia Prurigo Nodularis Treatment Market Value Share, By Drug Class, 2020 (E)

Figure 38: South Asia Prurigo Nodularis Treatment Market Value Share, By Distribution Channel, 2020 (E)

Figure 39: South Asia Prurigo Nodularis Treatment Market Value Share, By Country, 2020 (E)

Figure 40: South Asia Prurigo Nodularis Treatment Market Value Analysis (US$ Mn), 2015-2019

Figure 41: South Asia Prurigo Nodularis Treatment Market Value Forecast (US$ Mn), 2020-2030

Figure 42: South Asia Prurigo Nodularis Treatment Market Attractiveness Analysis By Drug Class, 2020-2030

Figure 43: South Asia Prurigo Nodularis Treatment Market Attractiveness Analysis by Distribution Channel, 2020-2030

Figure 44: South Asia Prurigo Nodularis Treatment Market Attractiveness Analysis by Country, 2020-2030

Figure 45: East Asia Prurigo Nodularis Treatment Market Value Share, By Drug Class, 2020 (E)

Figure 46: East Asia Prurigo Nodularis Treatment Market Value Share, By Distribution Channel, 2020 (E)

Figure 47: East Asia Prurigo Nodularis Treatment Market Value Share, By Country, 2020 (E)

Figure 48: East Asia Prurigo Nodularis Treatment Market Value Analysis (US$ Mn), 2015-2019

Figure 49: East Asia Prurigo Nodularis Treatment Market Value Forecast (US$ Mn), 2020-2030

Figure 50: East Asia Prurigo Nodularis Treatment Market Attractiveness Analysis By Drug Class, 2020-2030

Figure 51: East Asia Prurigo Nodularis Treatment Market Attractiveness Analysis by Distribution Channel, 2020-2030

Figure 52: East Asia Prurigo Nodularis Treatment Market Attractiveness Analysis by Country, 2020-2030

Figure 53: Oceania Prurigo Nodularis Treatment Market Value Share, By Drug Class, 2020 (E)

Figure 54: Oceania Prurigo Nodularis Treatment Market Value Share, By Distribution Channel, 2020 (E)

Figure 55: Oceania Prurigo Nodularis Treatment Market Value Share, By Country, 2020 (E)

Figure 56: Oceania Prurigo Nodularis Treatment Market Value Analysis (US$ Mn), 2015-2019

Figure 57: Oceania Prurigo Nodularis Treatment Market Value Forecast (US$ Mn), 2020-2030

Figure 58: Oceania Prurigo Nodularis Treatment Market Attractiveness Analysis By Drug Class, 2020-2030

Figure 59: Oceania Prurigo Nodularis Treatment Market Attractiveness Analysis by Distribution Channel, 2020-2030

Figure 60: Oceania Prurigo Nodularis Treatment Market Attractiveness Analysis by Country, 2020-2030

Figure 61: Middle East and Africa Prurigo Nodularis Treatment Market Value Share, By Drug Class, 2020 (E)

Figure 62: Middle East and Africa Prurigo Nodularis Treatment Market Value Share, By Distribution Channel, 2020 (E)

Figure 63: Middle East and Africa Prurigo Nodularis Treatment Market Value Share, By Country, 2020 (E)

Figure 64: Middle East and Africa Prurigo Nodularis Treatment Market Value Analysis (US$ Mn), 2015-2019

Figure 65: Middle East and Africa Prurigo Nodularis Treatment Market Value Forecast (US$ Mn), 2020-2030

Figure 66: Middle East and Africa Prurigo Nodularis Treatment Market Attractiveness Analysis By Drug Class, 2020-2030

Figure 67: Middle East and Africa Prurigo Nodularis Treatment Market Attractiveness Analysis by Distribution Channel, 2020-2030

Figure 68: Middle East and Africa Prurigo Nodularis Treatment Market Attractiveness Analysis by Country, 2020-2030

Figure 69: U.S. Prurigo Nodularis Treatment Market Share Analysis (%), by Drug Class, 2020 & 2030

Figure 70: U.S. Prurigo Nodularis Treatment Market Share Analysis (%), by Distribution Channel, 2020 & 2030

Figure 71: U.S. Prurigo Nodularis Treatment Market Value Analysis (US$ Mn), 2020 & 2030

Figure 72: Canada Prurigo Nodularis Treatment Market Share Analysis (%), by Drug Class, 2020 & 2030

Figure 73: Canada Prurigo Nodularis Treatment Market Share Analysis (%), by Distribution Channel, 2020 & 2030

Figure 74: Canada Prurigo Nodularis Treatment Market Value Analysis (US$ Mn), 2020 & 2030

Figure 75: Mexico Prurigo Nodularis Treatment Market Share Analysis (%), by Drug Class, 2020 & 2030

Figure 76: Mexico Prurigo Nodularis Treatment Market Share Analysis (%), by Distribution Channel, 2020 & 2030

Figure 77: Prurigo Nodularis Treatment Market Value Analysis (US$ Mn), 2020 & 2030

Figure 78: Brazil Prurigo Nodularis Treatment Market Share Analysis (%), by Drug Class, 2020 & 2030

Figure 79: Brazil Prurigo Nodularis Treatment Market Share Analysis (%), by Distribution Channel, 2020 & 2030

Figure 80: Brazil Nodularis Treatment Market Value Analysis (US$ Mn), 2020 & 2030

Figure 81: Germany Prurigo Nodularis Treatment Market Share Analysis (%), by Drug Class, 2020 & 2030

Figure 82: Germany Prurigo Nodularis Treatment Market Share Analysis (%), by Distribution Channel, 2020 & 2030

Figure 83: Germany Nodularis Treatment Market Value Analysis (US$ Mn), 2020 & 2030

Figure 84: Italy Prurigo Nodularis Treatment Market Share Analysis (%), by Drug Class, 2020 & 2030

Figure 85: Italy Prurigo Nodularis Treatment Market Share Analysis (%), by Distribution Channel, 2020 & 2030

Figure 86: Italy Nodularis Treatment Market Value Analysis (US$ Mn), 2020 & 2030

Figure 87: France Prurigo Nodularis Treatment Market Share Analysis (%), by Drug Class, 2020 & 2030

Figure 88: France Prurigo Nodularis Treatment Market Share Analysis (%), by Distribution Channel, 2020 & 2030

Figure 89: France Nodularis Treatment Market Value Analysis (US$ Mn), 2020 & 2030

Figure 90: U.K. Prurigo Nodularis Treatment Market Share Analysis (%), by Drug Class, 2020 & 2030

Figure 91: U.K. Prurigo Nodularis Treatment Market Share Analysis (%), by Distribution Channel, 2020 & 2030

Figure 92: U.K. Nodularis Treatment Market Value Analysis (US$ Mn), 2020 & 2030

Figure 93: Spain Prurigo Nodularis Treatment Market Share Analysis (%), by Drug Class, 2020 & 2030

Figure 94: Spain Prurigo Nodularis Treatment Market Share Analysis (%), by Distribution Channel, 2020 & 2030

Figure 95: Spain Nodularis Treatment Market Value Analysis (US$ Mn), 2020 & 2030

Figure 96: Russia Prurigo Nodularis Treatment Market Share Analysis (%), by Drug Class, 2020 & 2030

Figure 97: Russia Prurigo Nodularis Treatment Market Share Analysis (%), by Distribution Channel, 2020 & 2030

Figure 98: Russia Nodularis Treatment Market Value Analysis (US$ Mn), 2020 & 2030

Figure 99: China Prurigo Nodularis Treatment Market Share Analysis (%), by Drug Class, 2020 & 2030

Figure 100: China Prurigo Nodularis Treatment Market Share Analysis (%), by Distribution Channel, 2020 & 2030

Figure 101: China Nodularis Treatment Market Value Analysis (US$ Mn), 2020 & 2030

Figure 102: Japan Prurigo Nodularis Treatment Market Share Analysis (%), by Drug Class, 2020 & 2030

Figure 103: Japan Prurigo Nodularis Treatment Market Share Analysis (%), by Distribution Channel, 2020 & 2030

Figure 104: Japan Nodularis Treatment Market Value Analysis (US$ Mn), 2020 & 2030

Figure 105: South Korea Prurigo Nodularis Treatment Market Share Analysis (%), by Drug Class, 2020 & 2030

Figure 106: South Korea Prurigo Nodularis Treatment Market Share Analysis (%), by Distribution Channel, 2020 & 2030

Figure 107: South Korea Nodularis Treatment Market Value Analysis (US$ Mn), 2020 & 2030

Figure 108: India Prurigo Nodularis Treatment Market Share Analysis (%), by Drug Class, 2020 & 2030

Figure 109: India Prurigo Nodularis Treatment Market Share Analysis (%), by Distribution Channel, 2020 & 2030

Figure 110: India Nodularis Treatment Market Value Analysis (US$ Mn), 2020 & 2030

Figure 111: Thailand Prurigo Nodularis Treatment Market Share Analysis (%), by Drug Class, 2020 & 2030

Figure 112: Thailand Prurigo Nodularis Treatment Market Share Analysis (%), by Distribution Channel, 2020 & 2030

Figure 113: Thailand Nodularis Treatment Market Value Analysis (US$ Mn), 2020 & 2030

Figure 114: Malaysia Prurigo Nodularis Treatment Market Share Analysis (%), by Drug Class, 2020 & 2030

Figure 115: Malaysia Prurigo Nodularis Treatment Market Share Analysis (%), by Distribution Channel, 2020 & 2030

Figure 116: Malaysia Nodularis Treatment Market Value Analysis (US$ Mn), 2020 & 2030

Figure 117: Indonesia Prurigo Nodularis Treatment Market Share Analysis (%), by Drug Class, 2020 & 2030

Figure 118: Indonesia Prurigo Nodularis Treatment Market Share Analysis (%), by Distribution Channel, 2020 & 2030

Figure 119: Indonesia Nodularis Treatment Market Value Analysis (US$ Mn), 2020 & 2030

Figure 120: Australia Prurigo Nodularis Treatment Market Share Analysis (%), by Drug Class, 2020 & 2030

Figure 121: Australia Prurigo Nodularis Treatment Market Share Analysis (%), by Distribution Channel, 2020 & 2030

Figure 122: Australia Nodularis Treatment Market Value Analysis (US$ Mn), 2020 & 2030

Figure 123: GCC Countries Prurigo Nodularis Treatment Market Share Analysis (%), by Drug Class, 2020 & 2030

Figure 124: GCC Countries Prurigo Nodularis Treatment Market Share Analysis (%), by Distribution Channel, 2020 & 2030

Figure 125: GCC Countries Nodularis Treatment Market Value Analysis (US$ Mn), 2020 & 2030

Figure 126: South Africa Prurigo Nodularis Treatment Market Share Analysis (%), by Drug Class, 2020 & 2030

Figure 127: South Africa Prurigo Nodularis Treatment Market Share Analysis (%), by Distribution Channel, 2020 & 2030

Figure 128: South Africa Nodularis Treatment Market Value Analysis (US$ Mn), 2020 & 2030

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports
Google translate

Prurigo Nodularis Treatment Market